Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...

The study aims to accrue up to 41 patients at MD Anderson Cancer Center and partner sites. The study started enrolling in October 2024, and enrollment is ongoing with a primary completion estimate of ...

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

The U54 ROBIN consortium is a first-of-its-kind effort to study the biological effects of radiation before, during, and after treatment, using small study cohorts for detailed molecular ...

Enrollment was between October 2019 and December 2023, during which time 41 patients were assessed for eligibility and 32 patients were enrolled. The median age was 74.0 years (range: 61.0-82.0), the ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

The MARCAP Consortium is the largest independent data repository and statistical analysis team, with Dr. Spratt and Dr. Amar ...